PRESS INFORMATION BUREAU থের মুখনা কার্যানেয GOVERNMENT OF INDIA খাবে ম্বকাব

MINT, Delhi Wednesday 28th January 2015, Page: 14 Width: 9.42 cms, Height: 3.57 cms, a4, Ref: pmin.2015-01-28.40.58

## Cipla shares rise after Teva approval

Mumbai: Shares of Cipla Ltd rose 4.62% to close at ₹705.95 on the BSE on Tuesday after the US Food and Drug Administration (FDA) permitted Teva Pharmaceuticals industries Ltd to sell a generic version of AstraZeneca Pic's blockbuster heartburn drug Nexium in the US for an exclusive six-month period. Cipla will manufacture the drug for Teva under an existing agreement. The revenue expected from exclusive sales of the Nexium generic in the US is estimated at around \$170 million. C.H. UNNIKRISHNAN

Country